Haemonetics Corp (HAE) Stock Analysis and Metrics

Haemonetics

NYSE: HAE

$78.78 ▲ +1.38 (+1.78%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap3.50 Bn

P/E37.52

P/S2.63

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)1.22 Bn

Revenue Growth (1y) (Qtr)4.76

Add ratio to table…

About

Haemonetics Corporation is a global medical technology company dedicated to improving the quality effectiveness and efficiency of health care. The company designs develops manufactures and markets innovative medical devices and disposables that address critical needs in blood management plasma collection and hospital-based interventions. Its products are used to enhance patient outcomes and support clinical workflows across diverse healthcare settings.

Haemonetics generates revenue through the sale of its medical technologies including plasma collection devices and disposables donor management software blood collection and processing systems and hospital-focused product lines. The company serves customers worldwide through a combination of direct sales teams and independent distributors with operations spanning approximately 96 countries. Revenue is derived from recurring sales of consumables and occasional capital equipment placements.

The company operates through the following segments: Plasma Blood Center and Hospital.

• The Plasma segment includes plasma collection devices and disposables donor management software and supporting software solutions sold to plasma customers. This segment focuses on enabling efficient and safe plasma collection operations for plasma centers.

• The Blood Center segment includes blood collection and processing devices and disposables for plasma red cells and platelets. This segment supports blood centers in collecting and preparing essential blood components for transfusion medicine.

• The Hospital segment is comprised of Interventional Technologies which includes Vascular Closure Sensor-Guided Technologies and Esophageal Protection product lines and Blood Management Technologies which includes Hemostasis Management Cell Salvage and Transfusion Management product lines. This segment provides solutions aimed at improving surgical outcomes and patient safety in hospital environments.

Haemonetics holds a strong position in the medical technology industry particularly in niche markets related to blood and plasma management. The company competes with established players such as Terumo BCT Fresenius Kabi and Abbott Laboratories while differentiating itself through specialized product portfolios and a focus on clinical efficiency and blood safety. Its strategic emphasis on high-growth areas like Plasma and Hospital segments reflects its commitment to innovation and long-term value creation.

The company serves a diverse customer base including plasma collection centers blood centers hospitals and healthcare providers. Specific customer names are not disclosed in the filing but the company indicates it works with major plasma operators healthcare systems and medical institutions globally to deliver its technologies and support operational needs.

Investment Thesis

▲ Bull case

Haemonetics' core growth platforms are showing strong and sustainable momentum that the market may not fully appreciate, particularly in the plasma and TEG franchises, which are driving both revenue and margin expansion. The company reported 13% organic ex-CSL growth in plasma for Q4 FY26 and 20% for the full year, significantly exceeding its prior guidance range of 17% to 19%, underscoring robust demand and successful execution of its innovation-led strategy. The Persona PLUS platform, which delivers an average additional 5% yield over the previous Persona system, is already seeing strong customer adoption and upgrade cycles underway, with management explicitly stating that price will be part of the equation as value is delivered to customers, creating potential for revenue upside beyond current guidance. Furthermore, Haemonetics' U.S. plasma collection share grew in the high single digits and European plasma grew at double-digit rates, indicating meaningful share gains in a structurally attractive market driven by resilient immunoglobulin demand and global expansion in plasma collections, which are not fully captured in the conservative 0% to 2% collection volume assumption embedded in FY27 guidance.
The interventional technologies (IVT) segment is poised for a meaningful reacceleration in growth as transient headwinds have now lapsed, setting the stage for durable recovery and upside potential in FY27 and beyond. Management explicitly stated that approximately 80% of the 9% full-year IVT revenue decline in FY26 was driven by two factors: OEM-related softness in sensor-guided technologies (due to J&J's acquisition of Abiomed) and PFA impacts on esophageal cooling, both of which have now been lapped or reduced to a nonmaterial base. With the VASCADE MVP XL label expansion already cleared and the PerQseal Elite large-bore closure device under FDA review, the company is strengthening its competitive position and reenergizing the business as it enters FY27. The CEO described Q4 FY26 as the inflection point for IVT, noting a return to growth at or above market rates for vascular closure led by electrophysiology, disproportionate growth in the SavvyWire direct retail business, and the anticipated launch of PerQseal Elite later in the year, which addresses a novel offering for large-bore closure with a total addressable market estimated at roughly $300 million. This combination of resolved headwinds, new product catalysts, and improved commercial execution suggests the market may be underestimating the segment's recovery trajectory.
Haemonetics' capital allocation strategy is creating significant shareholder value through disciplined buybacks and strategic acquisitions, while maintaining a strong balance sheet and generating robust free cash flow, yet the market may not be fully crediting the durability of this approach. In FY26, the company deployed $175 million for share repurchases (over 3 million shares bought back) and $61 million for the Vivasure acquisition, ending the year with $245 million in cash and generating $210 million in free cash flow for the year at an impressive 89% conversion ratio relative to adjusted net income. Despite carrying $1.2 billion in total debt, net leverage stands at a manageable 2.73x EBITDA, and the company has refinanced $300 million of convertible notes into the revolver, enhancing structural flexibility. With the CSL transition and whole blood divestiture now fully behind management, FY27 is positioned as a clean year without portfolio transition headwinds, allowing the company to focus on durable growth, cash flow generation, and return on capital. The guidance for FY27 free cash flow conversion of approximately 80% reflects conservatism due to increased inventory requirements, but the underlying cash generation strength remains a defining characteristic of the business, providing ample capacity for deleveraging, organic investment, and opportunistic shareholder returns.

Haemonetics' core growth platforms are showing strong and sustainable momentum that the market may not fully appreciate, particularly in the plasma and TEG franchises, which are driving both revenue and margin expansion. The company reported 13% organic ex-CSL growth in plasma for Q4 FY26 and 20% for the full year, significantly exceeding its prior guidance range of 17% to 19%, underscoring robust demand and successful execution of its innovation-led strategy. The Persona PLUS platform, which delivers an average additional 5% yield over the previous Persona system, is already seeing strong customer adoption and upgrade cycles underway, with management explicitly stating that price will be part of the equation as value is delivered to customers, creating potential for revenue upside beyond current guidance. Furthermore, Haemonetics' U.S. plasma collection share grew in the high single digits and European plasma grew at double-digit rates, indicating meaningful share gains in a structurally attractive market driven by resilient immunoglobulin demand and global expansion in plasma collections, which are not fully captured in the conservative 0% to 2% collection volume assumption embedded in FY27 guidance.
The interventional technologies (IVT) segment is poised for a meaningful reacceleration in growth as transient headwinds have now lapsed, setting the stage for durable recovery and upside potential in FY27 and beyond. Management explicitly stated that approximately 80% of the 9% full-year IVT revenue decline in FY26 was driven by two factors: OEM-related softness in sensor-guided technologies (due to J&J's acquisition of Abiomed) and PFA impacts on esophageal cooling, both of which have now been lapped or reduced to a nonmaterial base. With the VASCADE MVP XL label expansion already cleared and the PerQseal Elite large-bore closure device under FDA review, the company is strengthening its competitive position and reenergizing the business as it enters FY27. The CEO described Q4 FY26 as the inflection point for IVT, noting a return to growth at or above market rates for vascular closure led by electrophysiology, disproportionate growth in the SavvyWire direct retail business, and the anticipated launch of PerQseal Elite later in the year, which addresses a novel offering for large-bore closure with a total addressable market estimated at roughly $300 million. This combination of resolved headwinds, new product catalysts, and improved commercial execution suggests the market may be underestimating the segment's recovery trajectory.
Haemonetics' capital allocation strategy is creating significant shareholder value through disciplined buybacks and strategic acquisitions, while maintaining a strong balance sheet and generating robust free cash flow, yet the market may not be fully crediting the durability of this approach. In FY26, the company deployed $175 million for share repurchases (over 3 million shares bought back) and $61 million for the Vivasure acquisition, ending the year with $245 million in cash and generating $210 million in free cash flow for the year at an impressive 89% conversion ratio relative to adjusted net income. Despite carrying $1.2 billion in total debt, net leverage stands at a manageable 2.73x EBITDA, and the company has refinanced $300 million of convertible notes into the revolver, enhancing structural flexibility. With the CSL transition and whole blood divestiture now fully behind management, FY27 is positioned as a clean year without portfolio transition headwinds, allowing the company to focus on durable growth, cash flow generation, and return on capital. The guidance for FY27 free cash flow conversion of approximately 80% reflects conservatism due to increased inventory requirements, but the underlying cash generation strength remains a defining characteristic of the business, providing ample capacity for deleveraging, organic investment, and opportunistic shareholder returns.

▼ Bear case

Haemonetics' plasma growth narrative may be overstated due to unsustainable tailwinds and hidden vulnerabilities in the fractionation market that management did not adequately address, particularly regarding pricing pressure and shifting therapeutic landscapes. While the company highlighted strong organic plasma growth and share gains, it acknowledged that collection volume growth assumptions in FY27 guidance are deliberately conservative at 0% to 2%, implicitly admitting that it cannot control this critical driver. More concerning is the unaddressed risk of fractionator discounting, which was raised by an analyst but dismissed without concrete data on finished good immunoglobulin inventory levels or the impact of FcRn competition in CIDP indications. Management's dismissal of FcRn biosimilar competition as irrelevant because "both can grow" overlooks the potential for therapy switching in responsive patients and the broader trend toward cost containment in healthcare, which could exert downward pressure on plasma collection pricing or volumes. Additionally, the company's reliance on innovation-based pricing via Persona PLUS to drive margin expansion assumes customers will accept higher prices for increased yield, yet prior yield rollouts led some large collectors to reduce total collections to meet annual objectives, creating a direct trade-off between yield enhancement and volume that could undermine long-term plasma growth sustainability.
The interventional technologies (IVT) recovery thesis is overly optimistic and ignores persistent structural challenges in the vascular closure market that could limit growth despite recent product launches and label expansions. Management attributed the bulk of FY26 IVT decline to transient OEM softness and PFA impacts on esophageal cooling, both of which they claim have lapsed, but this narrative downplays the ongoing structural shift caused by pulsed field ablation (PFA) adoption, which fundamentally reduces access site demand for closure products—a trend that is not merely cyclical but procedural. While they noted that access site growth was likely mid-single digits in FY26 (as low as 3.5% to 4%) and expect higher growth in FY27, they provided no evidence that the underlying EP procedure volume growth will accelerate sufficiently to offset the reduced closure demand per procedure. Furthermore, the MVP XL label expansion, while clinically meaningful, serves an electrophysiology niche that remains vulnerable to PFA displacement, and the PerQseal Elite device, despite its estimated $300 million TAM, faces uncertain FDA timelines and significant commercialization risks, including the need for manufacturing scale-up and cost of goods sold reduction to achieve margin accretivity—factors that suggest near-term revenue contribution may be minimal and profitability delayed.
Haemonetics' margin expansion guidance for FY27 is vulnerable to multiple macroeconomic and operational headwinds that could erode profitability despite portfolio improvements, particularly tariff impacts and rising labor and tax costs. The company disclosed that Q4 operating margin declined 50 basis points year-over-year due to higher-than-anticipated tariffs (with roughly 60% of annual impact felt in Q4 as plasma inventories were depleted), increased self-insured medical claims expenses, and stepped-up sales and marketing investments ahead of FY27 launches. For FY27, they are assuming a 15% tariff level versus the current 10%, building in this differential as a known offset to gross margin expansion from plasma innovation and favorable mix shifts. Additionally, they expect adjusted EPS to grow in line with revenue despite a projected 100 basis point increase in the tax rate, which will directly counteract operating leverage and mix benefits. The 80% free cash flow conversion target for FY27, down from 89% in FY26, reflects conservatism around increased inventory requirements, but this also signals working capital pressure that could constrain cash generation if inventory build-out does not translate into timely revenue conversion. Combined with ongoing ERP-related costs and the dilutive impact of the Vivasure acquisition (estimated at $0.20 per share for FY27), these factors suggest margin expansion may be slower and less certain than guidance implies.

Haemonetics' plasma growth narrative may be overstated due to unsustainable tailwinds and hidden vulnerabilities in the fractionation market that management did not adequately address, particularly regarding pricing pressure and shifting therapeutic landscapes. While the company highlighted strong organic plasma growth and share gains, it acknowledged that collection volume growth assumptions in FY27 guidance are deliberately conservative at 0% to 2%, implicitly admitting that it cannot control this critical driver. More concerning is the unaddressed risk of fractionator discounting, which was raised by an analyst but dismissed without concrete data on finished good immunoglobulin inventory levels or the impact of FcRn competition in CIDP indications. Management's dismissal of FcRn biosimilar competition as irrelevant because "both can grow" overlooks the potential for therapy switching in responsive patients and the broader trend toward cost containment in healthcare, which could exert downward pressure on plasma collection pricing or volumes. Additionally, the company's reliance on innovation-based pricing via Persona PLUS to drive margin expansion assumes customers will accept higher prices for increased yield, yet prior yield rollouts led some large collectors to reduce total collections to meet annual objectives, creating a direct trade-off between yield enhancement and volume that could undermine long-term plasma growth sustainability.
The interventional technologies (IVT) recovery thesis is overly optimistic and ignores persistent structural challenges in the vascular closure market that could limit growth despite recent product launches and label expansions. Management attributed the bulk of FY26 IVT decline to transient OEM softness and PFA impacts on esophageal cooling, both of which they claim have lapsed, but this narrative downplays the ongoing structural shift caused by pulsed field ablation (PFA) adoption, which fundamentally reduces access site demand for closure products—a trend that is not merely cyclical but procedural. While they noted that access site growth was likely mid-single digits in FY26 (as low as 3.5% to 4%) and expect higher growth in FY27, they provided no evidence that the underlying EP procedure volume growth will accelerate sufficiently to offset the reduced closure demand per procedure. Furthermore, the MVP XL label expansion, while clinically meaningful, serves an electrophysiology niche that remains vulnerable to PFA displacement, and the PerQseal Elite device, despite its estimated $300 million TAM, faces uncertain FDA timelines and significant commercialization risks, including the need for manufacturing scale-up and cost of goods sold reduction to achieve margin accretivity—factors that suggest near-term revenue contribution may be minimal and profitability delayed.
Haemonetics' margin expansion guidance for FY27 is vulnerable to multiple macroeconomic and operational headwinds that could erode profitability despite portfolio improvements, particularly tariff impacts and rising labor and tax costs. The company disclosed that Q4 operating margin declined 50 basis points year-over-year due to higher-than-anticipated tariffs (with roughly 60% of annual impact felt in Q4 as plasma inventories were depleted), increased self-insured medical claims expenses, and stepped-up sales and marketing investments ahead of FY27 launches. For FY27, they are assuming a 15% tariff level versus the current 10%, building in this differential as a known offset to gross margin expansion from plasma innovation and favorable mix shifts. Additionally, they expect adjusted EPS to grow in line with revenue despite a projected 100 basis point increase in the tax rate, which will directly counteract operating leverage and mix benefits. The 80% free cash flow conversion target for FY27, down from 89% in FY26, reflects conservatism around increased inventory requirements, but this also signals working capital pressure that could constrain cash generation if inventory build-out does not translate into timely revenue conversion. Combined with ongoing ERP-related costs and the dilutive impact of the Vivasure acquisition (estimated at $0.20 per share for FY27), these factors suggest margin expansion may be slower and less certain than guidance implies.

Segments Breakdown of Revenue (2026)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2026)

Segments Breakdown of Revenue (2026)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2026)

Segments Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password